novo oral glp-1 Semaglutide Approved to Reduce the Risk of Cardiovascular Events US FDA accepts Novo Nordisk's

No, but they should consult their healthcare provider to ensure safe and effective co-prescribing

Ozempic lawsuits allege Novo Nordisk failed to adequately warn patients and healthcare providers about serious gastrointestinal risks including gastroparesis, pancreatitis, bowel obstruction, and vision loss (NAION)

In addition

Studies conducted in rodents show improved metabolic profiles using 11-HSD 1 inhibition

Unlike semaglutide which solely activates GLP-1R (one of the three pivotal receptors regulating glucose homeostasis), tirzepatide also activates glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) to enhance metabolic benefits with reduced side-effects 5

In addition, the Shannon indexes of the CB0313.1-treated group were significantly higher than for the HF diabetic control group, even higher than ND-fed mice, indicating increased diversity of the gut microbiota in the CB0313.1-treated group (Fig